Introduction: FL has heterogeneous biological behavior, variable clinical outcomes, and a natural history marked by histological transformation (HT). Clinical-laboratory, genetic, epigenetic, and TME factors strongly influence its biological diversity and prognosis. The management of FL and its outcomes are highly dependent on staging (CS) and tumor burden (TB). The identification of new molecular biomarkers is crucial, not only to understand FL's biology, but also, can guide better prognostic stratification, as well as determine new therapeutic targets. Therefore, the present study aims to outline the GEP in tissue samples from FL categorized by CS and TB using a large-scale gene microarray platform with subsequent expansion by RT-qPCR.

Methods: This translational study involved 219 FL cases, treated at University of São Paulo, from 2006 to 2022. FL patients were categorized into early-stage disease (I/II) (ES), advanced-stage (AS) (III/IV) with low tumor burden (LTB), and AS with high tumor burden (HTB) according to the GELF criteria. The experimental phase involved 126 FFPE samples. Firstly, 42 samples (12 ES, 11 AS-LTV, 12 AS-HTV, 6 control lymph nodes and 1 control HELA) were submitted to the array protocol using the Clariom D Array Human platform. The identification of differentially expressed genes (DEGs) between the 4 groups used the Transcriptome Analysis Console by the eBay ANOVA method. Bidimensional Principal Component Analysis (PCA) sought to identify discriminatory DEGs clusters between the groups. A comparative analysis between pairs was subsequently performed. The 7 most discriminatory DEGs and 3 endogenous genes (GAPDH, GUSB and ACTB) were selected for a cohort expansion phase by RT-qPCR. The Kruskal-Wallis test was used to evaluate differences in DEGs expression between the groups and Mann-Whitney test to test associations between DEGs and phenotypic-prognostic characteristics, p-value ≤ 0.05 was considered significant.

Results: According to CS and TB, 14.6% (32/219) FL cases were categorized as ES, 17.8% (39/219) as AS-LTB, and 67.6% (148/219) as AS-HTB. With a median follow-up of 80.7 months, the median OS was 208.2 months, 130.5 months, and 126.3 months for ES, AS-LTB, and AS-HTB, respectively, p=0.249. The median PFS was 113.3 months, 110.7 months, and 59.5 months, respectively, for the same groups, p=0.018. The array protocol identified 135,750 genes comparisons between the control, ES, AS-LTB, and AS-HTB. Bidimensional PCA analysis was not able to identify discriminatory DEGs clusters among the 4 groups. Pairwise comparative analysis identified 1913 DEGs among the 4 groups. Of these, 1759 (91.9%) were DEGs between FL and healthy controls, but only 218 (11.3%) were DEGs among the 3 different FL subgroups (ES, AS-LTB, and AS-HTB), evidencing a low molecular diversity in FL when categorized by CS and TB. In the cohort expansion phase by qRT-PCR, 7 pre-selected DEGs based on the microarray results were tested, including the genes GNG7, ITGAM, AZN1, TIMD4, IL7R, PTGS2, and MTTL10. The comparison between the median expression of these genes among the 3 FL's groups showed that the expression of the ILR7 gene was downregulated with the progression of the disease, with marked hypoexpression in AS-HTB patients. These data may suggest downregulation of IL7R gene in the FL´s natural history. Additionally, we found that hypoexpression of the GNG7 (p=0.024) and PTGS2 (p=0.090) were associated with higher rates of disease progression/relapse, and hypoexpression of the GNG7 (p=0.006) was associated with a higher probability of HT, highlighting the potential prognostic impact of these molecular biomarkers. Finally, we established phenotypic-genotypic associations, as hypoexpression of ITGAM was associated with higher rates of B-symptoms (p=0.017) and bulky disease (p=0.026), as well as hypoexpression of IL7R was correlated with a higher probability of bulky (p=0.025) and extranodal involvement (p=0.016).

Conclusion: Although clinical staging and disease burden are strong determinants of the prognostic heterogeneity of FL, this study did not find high molecular diversity by this categorization. We observed a relatively homogeneous GEP with low biological diversity in FL presenting different disease evolution phases. Moreover, new molecular biomarkers potentially implicated in FL´s natural history, prognostication and specific clinical phenotypes were revealed.

Disclosures

Rocha:Pfizer: Consultancy; Astellas: Consultancy; AbbVie: Consultancy; Amgen: Consultancy; Takeda: Consultancy; Kite: Consultancy.

This content is only available as a PDF.
2024
Sign in via your Institution